Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression

Completed · Phase 3

Conditions studied: Depressive Disorder, Depression

In brief

The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.

Key facts

Study ID

NCT00096798

Run by

National Center for Complementary and Integrative Health (NCCIH)

People needed

80

Starts

2001-09-01

Expected to finish

2007-08-01

Last updated by the study team

2008-01-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Major depressive disorder

You may not qualify if…

• Serious comorbid psychiatric disorder
• Unstable medical illness
• Prior use of any omega-3 fatty acid product

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.